


**CLAIMS**

1. A compound of formula I



wherein

R is  $\text{CH}_3$ ,  $(\text{CH}_2)_n\text{I}$ ,  $(\text{CH}_2)_n\text{Br}$  or  $(\text{CH}_2)_n\text{F}$ , n being 1, 2, 3 or 4

in free base or acid addition salt form.


2. A compound according to claim 1, wherein

R is  $^{11}\text{CH}_3$ ,  $(^3\text{H})_3\text{C}$ ,  $(\text{CH}_2)_n^{123}\text{I}$ ,  $(\text{CH}_2)_n^{76}\text{Br}$  or  $(\text{CH}_2)_n^{18}\text{F}$ , n being 1, 2, 3 or 4

in free base or acid addition salt form.


3. A process for the production of a compounds of formula I as defined in claim 1, or a salt thereof, comprising the step of

a) for the production of a compound of formula Ia




- 9 -

wherein  $R_a$  is respectively  $^{11}\text{CH}_3$  or  $(^3\text{H})_3\text{C}$ , reacting the compound of formula II




with respectively  $^{11}\text{CH}_3\text{I}$  or  $\text{C}(^3\text{H})_3\text{I}$ , in the presence of a base, or


b) for the production of a compound of formula Ib



wherein Rb is respectively  $(\text{CH}_2)_n^{18}\text{F}$ ,  $(\text{CH}_2)_n^{123}\text{I}$  or  $(\text{CH}_2)_n^{76}\text{Br}$ , reacting a compound of formula III



wherein n is as defined in claim 1 and X is OTs or OMs, with respectively  $^{18}\text{F}^\ominus$ ,  $^{123}\text{I}^\ominus$  or  $^{76}\text{Br}^\ominus$ , or reacting the compound of formula II with a compound of formula IV



IV

wherein X and Rb are as defined above,

- 10 -

and recovering the resulting compound of formula I in free base form or in form of an acid addition salt.

4. A compound of formula I as defined in claim 1, in free base or acid addition salt form, for use as a marker for neuroimaging.
5. A composition for labeling brain and peripheral nervous system structures involving mGlu5 receptors *in vivo* and *in vitro* comprising a compound of formula I as defined in claim 1, in free base or acid addition salt form.
6. A method for labeling brain and peripheral nervous system structures involving mGlu5 receptors *in vitro* or *in vivo*, which comprises contacting brain tissue with a compound of formula I as defined in claim 1, in free base or acid salt form.